Advanced Search

 

Study ID Status Title Patient Level Data
SAS10019 Completed A repeat dose, randomised, double blind, 2-way crossover study to assess the safety and systemic exposure of an investigational formulation compared to concurrent administration of individual Fluticasone Propionate 50 and Salmeterol 50 DISKUS inhalers in subjects aged 18 - 55 years with mild asthma Study Listed on ClinicalStudyDataRequest.com
SAS104449 Completed A randomised, open label, five-way crossover study to assess the systemic exposure of fluticasone propionate and salmeterol from SERETIDE/ADVAIR 250HFA MDI alone and with AeroChamber-Max spacer and VOLUMATIC both in their washed and unwashed states in adult subjects with mild or intermittent asthma Study Listed on ClinicalStudyDataRequest.com
SAS105519 Completed A repeat-dose, open-label, randomized, incomplete block design in pediatric subjects with asthma, ages 4 - 11 years, to compare systemic exposure and pharmacodynamics of fluticasone propionate and salmeterol following Advair HFA 45/21mcg (2 inhalations), ADVAIR® HFA 45/21mcg (2 inhalations) with Aerochamber Plus Spacer and Advair Diskus 100/50 twice daily Study Listed on ClinicalStudyDataRequest.com
SAS107541 Completed A long term follow up study for a comparison of stepwise treatment of asthmatic children with Salmeterol/Fluticasone propionate combination product (SERETIDE®) and/or Fluticasone propionate (FLIXOTIDE (TM)) based on PD20 methacholine and symptoms or based on symptoms only.
SAS30018 Completed Comparison of stepwise treatment of asthmatic children with Salmeterol/Fluticasone propionate combination product (Seretide®) and/or Fluticasone propionate (Flixotide®) based on PD20 methacholine and symptoms or based on symptoms only (Children Asthma Therapy Optimal)
SAS30021 Completed A stratified, randomized, double-blind, placebo-controlled, parallel-group, 12 week trial evaluating the safety and efficacy of fluticasone propionate/salmeterol DISKUS combination product 100/50mcg once daily versus fluticasone propionate DISKUS 100mcg once daily and placebo in symptomatic pediatric subjects (4-11 years) with asthma Study Listed on ClinicalStudyDataRequest.com
SB 480848/035 Completed A Study to Evaluate the Effect of Repeat Oral Doses of Darapladib on Cardiac Conduction as Compared to Placebo and a Single Oral Dose of Moxifloxacin Study Listed on ClinicalStudyDataRequest.com
SB030002 Completed A Randomized, Double-Blind, Parallel-group, Multi-Center Study of Albuterol Sulfate HFA Inhalation Aerosol Delivered Cumulatively with a valved holding chamber and an attached facemask in subjects between birth to 23 months of age with acute wheezing due to obstructive airways disease Study Listed on ClinicalStudyDataRequest.com
SB223412/078 Completed A Multicenter, Double-Blind, Double-Dummy, Placebo-Controlled, Randomized, Parallel Group Evaluation of the Efficacy and Safety of a Fixed-Dose of Talnetant Versus Placebo Versus Risperidone in Subjects with Schizophrenia
SB-223412/093 Completed A Multicenter, Double-Blind, Double-Dummy, Placebo-Controlled, Randomized, Parallel Group Evaluation of the Efficacy and Safety of a Fixed-Dose of Talnetant Versus Placebo Versus Risperidone in Subjects with Schizophrenia
SB29060.833 Completed An open label study assessing Paxil CR (paroxetine CR) in patients with major depressive disorder who discontinued treatment with selective serotonin reuptake inhibitors or a selective serotonin/norepinephrine reuptake inhibitor due to intolerability
SB-462795/008 Completed An open-label, two-period, fixed sequence, randomized, parallel group, interaction study to determine the effects of repeat doses of relacatib on the metabolism of acetaminophen, ibuprofen and atorvastatin in healthy postmenopausal female subjects
SB-480848/026 Completed An International, Multicenter, Randomized, Placebo-controlled, Parallel-group, 1 Year Treatment, Integrated Biomarkers and Imaging Study in Subjects with Angiographically Documented Coronary Heart Disease (CHD) to Examine the Effects of the Novel Lipoprotein-associated Phospholipase A2 (Lp-PLA2) inhibitor SB-480848 on Intermediate Cardiovascular Endpoints, Patient Safety and Tolerability Study Listed on ClinicalStudyDataRequest.com
SB-485232/006 Completed A Phase II, Multi-center, Open-label, Randomized Study Evaluating the Anti-tumor Activity of SB-485232, rhIL-18, Administered as Five Daily Intravenous Infusions Every 28 Days in Subjects with Previously Untreated Metastatic Melanoma
SB681323/011 Completed An open label study to determine the excretion balance and pharmacokinetics of [14C]SB-681323, administered as a single dose of an oral solution to healthy adult male subjects.
SB-705498/008 Completed A single blind, placebo controlled, multi-centre study to investigate the pharmacokinetics, safety, tolerability and pharmacodynamics of the TRPV1 antagonist SB-705498 against the pain of acute migraine.
SB-714703/003 Completed An open, randomised, multi-centre dose ranging phase II study to evaluate LAPDAP in combination with three different doses of artesunate
SCA100223 Completed A Multicenter, Double-Blind, Placebo-Controlled, Fixed-Dose, 8-Week Evaluation of the Efficacy and Safety of Lamotrigine in the Treatment of Depression in Patients with Type II Bipolar Disorder Study Listed on ClinicalStudyDataRequest.com
SCA102833 Completed The Evaluation of Lamictal as an Add-on Treatment for Bipolar I Disorder in Children and Adolescents, 10 to 17 Years of Age Study Listed on ClinicalStudyDataRequest.com
SCA104753 Completed An Open-Label Extension Study to Assess the Safety of Lamotrigine in Subjects with Bipolar Disorder, who are in remission following a manic/hypomanic index episode or a depressive index episode.
SCA104779 Completed Study SCA104779, an evaluation of BW430C (lamotrigine) versus placebo in the prevention of mood episodes in bipolar I disorder patients Study Listed on ClinicalStudyDataRequest.com
SCA106052 Completed Study SCA106052, a clinical evaluation of BW430C (lamotrigine) in bipolar I disorder– Long-term extension study (extension of study SCA104779 (NCT00550407)) Study Listed on ClinicalStudyDataRequest.com
SCA30905 Completed A mulitcentre, double-blind, randomised, fixed-dose evaluation of the safety and efficacy of Lamictal (lamotrigine) compared to placebo as an add-on therapy to lithium or another mood stabiliser in the treatment of bipolar depression, followed by long-term prevention of relapse and recurrence of depression and/or mania in patients with bipolar disorder
SCA30924 Completed Double blind placebo controlled study of lamictal in acute bipolar depression Study Listed on ClinicalStudyDataRequest.com
SCA30926 Completed A Multi-Center, Double blind, Placebo-controlled, Randomized, Parallel Group Evaluation of the Efficacy of a Flexible Dose of Lamotrigine versus Placebo As Add-On Therapy In Schizophrenia Study Listed on ClinicalStudyDataRequest.com

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.